Articles tagged with Lung Cancer
A recent analysis of lung cancer screening studies found that CT scans do not save lives and may even be counterproductive. The study's authors estimated that between 4.1 and 5.5 patients per thousand would die of lung cancer after screening, similar to the mortality rate without screening.
The Tobacco industry's document depository in Guildford, UK, is being criticized for its limited access and transparency. The company has failed to provide electronic access to requested documents, despite claiming to have 'big time imaging' capabilities.
Researchers found that collecting comorbidity information from cancer registrars improves prognostic accuracy for various cancer types. Comorbidity data complements tumor stage in predicting patient outcomes.
A study by the American College of Radiology found that thoracic PET scans are suitable for diagnosing some lung cancer patients with localized disease. This approach reduces radiation exposure and saves time compared to whole-body PET examinations, which cover a broader area of the body.
The study found that combination PET/CT correctly identified 94% of malignant lesions, but only 36% of benign nodules. It also showed that the technique accurately determined the stage of cancer in 61 patients, but may overstage or understage tumors.
Researchers found a high correlation between EGFR mutations and sensitivity to gefitinib therapy in lung cancer patients, particularly in women and non-smokers. The study also revealed significant differences in response rates between Japanese and American patients, suggesting genetic variation plays a crucial role in drug effectiveness.
Researchers found that patients with certain EGFR gene mutations in non-small cell lung cancer (NSCLC) respond well to treatment with Iressa, a kinase blocker. The study identifies the potential for screening patients for these mutations to predict treatment response and benefits ethnic populations differently.
Researchers at MGH Cancer Center found that specific gene mutations in the EGFR gene predict responsiveness to Iressa, a targeted therapy that causes tumors to shrink significantly. The discovery will help determine which patients benefit from Iressa and potentially lead to new targeted therapies.
A $3.6M study aims to demonstrate the effectiveness of linking CT lung cancer screening to smoking-cessation programs. Dr. Claudia Henschke's research will use advanced image analysis software to investigate this connection.
A study found that tobacco smoke exposure is responsible for more than half the non-lung cancer death rate in African-American males, and up to two-thirds of their overall cancer death rate. The excess cancer burden can be clearly linked to smoking, with significant declines in mortality rates observed when smoking declined.
Researchers found that combining CT and PET scans significantly enhances radiologists' abilities to precisely define tumor locations for radiation treatments. This improves the efficacy of treatment and limits side effects in non-small-cell lung cancer patients. PET-CT scanning units are now available at hundreds of hospitals nationwide.
Women are more susceptible to lung cancer due to genetic mutations and hormonal changes, resulting in increased adenocarcinoma prevalence. Effective tobacco control measures are crucial to prevent a similar surge in lung cancer rates among women in developing countries.
A study examines the reasons behind the US epidemic of lung cancer in women, citing data on rising smoking rates and disproportionate impact on adenocarcinoma cases. The authors emphasize the need for more comprehensive research on lung cancer prevention and early diagnosis, particularly among women.
Women are more likely to develop lung cancer, with longer survival rates compared to men. Estrogen signaling and hormonal factors may play a role in these differences.
A recent study has found a dramatic increase in lung cancer incidence in women, with many cases occurring in non-smokers who stopped smoking years ago. The study also reveals that women's response to targeted therapies is more favorable than men, raising questions about the differences between male and female lung cancer.
Researchers found 53 smoking-induced genetic alterations in mice exposed to tobacco smoke, with CYP1B1 enzyme overexpression linked to estradiol activation. This finding may help understand why female smokers are more susceptible to lung cancer than male smokers.
A Wistar Institute-led team will develop blood tests to detect early lung cancer using proteomics and genomics, aiming to save lives through earlier cancer detection. The project receives $3.4M in funding from Pennsylvania's share of the national tobacco settlement.
A study found that gefitinib is effective for patients with non-small cell lung cancer who are female, never smoked, and have a specific type of cancer. The researchers identified two key factors associated with sensitivity to the drug: having adenocarcinoma with bronchioloalveolar features and never having smoked.
Researchers found that retinoblastoma survivors are at higher risk of epithelial cancers such as esophagus, stomach, colon, lung, breast, cervix, or prostate, despite low radiation therapy. High folate intake is associated with a lower risk of ovarian cancer, especially among women who consume alcohol.
A new theory by Steven Frank proposes that cancer progression speeds up with age, leading to increased incidence in older adults. As people age, fewer stages remain before cancer develops, resulting in higher cancer rates.
A team of researchers has developed a novel lung cancer treatment using nanoparticle cluster bombs, which have shown promise in treating cancerous lung cells. The new delivery system could potentially be used to target cancer cells while leaving healthy cells alone.
A recent study found that reducing cigarette consumption by 25%, 50%, and 75% did not proportionally decrease the levels of carcinogens in smokers' urine. Despite a reduction in cigarettes smoked per day, NNK metabolites remained relatively stable. The authors suggest that people may compensate for reduced smoking by inhaling longer an...
A Phase II trial of Herceptin combined with chemotherapy found no significant difference in survival times between the treatment and control arms. However, a small subgroup of patients with extremely high levels of HER2 over-expression showed improved response rates and longer disease progression-free periods.
The University Hospitals of Cleveland is using GE's RapidScreen Digital to improve lung cancer detection rates. The CAD system analyzes digital x-ray data and draws circles around suspicious regions, focusing radiologists on potential abnormalities.
A study of annual CT screenings found that 80% of diagnosed Stage I lung cancers were curable. Long-term follow-up showed a high cure rate for patients with screen-diagnosed lung cancer who underwent surgery. The findings support the use of widespread annual low-dose CT screening in high-risk smokers to detect early-stage lung cancer.
A recent study published by the Radiological Society of North America (RSNA) found that female smokers are twice as likely to develop lung cancer as male smokers, regardless of smoking habits, age, or nodule size. The study also revealed that increased smoking and aging significantly increase the risk of developing lung cancer.
A new study reveals that residents of Appalachia experience a disproportionate increase in cancer incidence, particularly lung, colon, rectum, and cervix cancers. The study found that rural residents had even higher rates of these cancers compared to the general population.
A new blood test detects mesothelioma at an early stage, potentially leading to improved patient outcomes. The test uses soluble mesothelin-related proteins (SMR) as a biomarker, which can detect the cancer several years before symptoms appear.
A Phase I study for non-small cell lung cancer used stereotactic radioablation, increasing radiation doses without prohibitive toxicity. 87% of patients showed positive tumor response, with no local recurrence at the highest dose levels.
A recent study found that people who underwent lung cancer screening were motivated to quit smoking. The study suggests that cancer screening may present an opportunity for health-care providers to offer smoking cessation resources.
Gefinitib, a designer drug targeting the epidermal growth factor receptor, has shown efficacy in treating advanced non-small cell lung cancer. In a phase II clinical trial, 43% of patients experienced symptom improvement and 12% showed partial radiographic responses.
A new study by Georgetown University Medical Center researchers found that low-dose CT screenings can accelerate smoking cessation rates by 14%, significantly higher than the national average. This promising finding suggests it's never too late to treat nicotine dependence, and further research may lead to more effective interventions.
A study by Temple University researchers identifies the molecular mechanisms that may assist the tumor-suppressing gene Rb2/p130 in blocking lung cancer cells. The study reveals nearly 70 genes regulated by Rb2, including previously known and unknown targets involved in lung cancer progression.
Researcher Dr. Mitra has developed an optical tomography method to locate lung tumors using short-pulse lasers. The technique yields physiological information with higher resolution and a safer system than traditional methods.
The SARS epidemic taught four important lessons: the need for global cooperation, improved public health infrastructure, care for patients despite personal risk, and measures to minimize infectious risks to healthcare workers. The response to SARS demonstrates that a strong public health infrastructure can help contain outbreaks and pr...
A study found that nearly 40% of lung cancer patients believe exposure to air during surgery promotes cancer spread, leading some to reject recommended surgery. The study suggests that physicians need to address these misconceptions to improve healthcare outcomes in African Americans, who are disproportionately affected by lung cancer.
A new trial found a significant survival benefit from adjuvant chemotherapy in non-small cell lung cancer, increasing patient lifespan by 4.1%. The study suggests that toxicity is still a major concern and calls for better tools to identify patients who will benefit from treatment.
Researchers at Duke University Medical Center have developed a new blood test that can detect lung cancer in its earliest stages using MALDI-TOF MS. The test targets serum amyloid A, a protein elevated in lung cancer patients' blood.
A study by Harvard and Queensland universities found that 4.8 million deaths in 2000 were caused by smoking, affecting both developed and developing countries. The majority of these deaths were among men, especially in less-developed nations.
A study published in The Journal of Nuclear Medicine found that 18F-FLT PET scans are more accurate than 18F-FDG PET scans in differentiating between cancerous and non-cancerous lung tumors. However, the researchers noted that 18F-FDG is still a reliable tool for staging tumors.
A new blood test can detect smokers with low levels of DNA repair enzyme OGG1, which increases their risk of lung cancer by 5-10 times. The test may help inform smoking cessation decisions for high-risk individuals.
Measuring DNA repair enzyme OGG activity found a significant association with lung cancer risk. Smokers and nonsmokers with low OGG activity had higher lung cancer risk compared to those with normal activity levels, with smokers being at greater risk due to smoking alone.
Researchers found that a combination of low-dose spiral CT and selective use of PET can effectively detect early-stage lung cancer in high-risk individuals. The study showed that lesions up to 5mm can be safely followed up after 12 months without major risks of progression.
A new study has found that a weekly regimen of paclitaxel and carboplatin is well-tolerated and effective in treating advanced non-small cell lung cancer. The treatment resulted in a response rate of 32% and median survival time of 49 weeks, with fewer side effects compared to standard regimens.
The EU's Europe Against Cancer Programme has shown promising results in reducing cancer deaths across most European countries. However, tobacco use still poses a significant threat to public health, with many countries experiencing declining trends in cancer death rates while others struggle with rising rates.
A study found a strong correlation between genetic polymorphisms in two genes and lung cancer risk in smokers. Mutations in both XPD and cyclin D1 (CCND1) occurred more often in lung cancer patients, increasing the risk of lung cancer among individuals with a smoking history.
Researchers found that the p53 gene plays a crucial role in distinguishing which lung cancer patients are most likely to survive four years or more. The study identified a sub-group of early-stage lung cancer patients without p53 mutations who had a significantly higher survival rate, providing hope for a new treatment approach.
The US Preventive Services Task Force recommends against use of beta-carotene supplements for cancer or cardiovascular disease prevention due to lack of benefit and potential harm. Lawsuits involving human subjects research are increasing, leading to more careful research and increased costs, according to experts.
A study found that PET-CT scans were more accurate than PET scans alone in staging non-small cell lung cancer patients. The combined imaging technique correctly identified lung cancer with chest wall and vascular spread, downgrading tumor severity in 13.3% of cases.
A new study suggests that the area where carcinogens settle may play a key role in developing lung cancer. The research found that cells located at carinal ridges can receive massive doses of toxic particulate matter, potentially leading to impaired mucociliary clearance and increased risk of neoplastic lesions.
The study found that BAC proliferation correlated with HER2 but not EGFR expression, suggesting a potential role for combination therapies. Researchers hope to launch a clinical trial of HER2- and EGFR-blocker combination therapy in the treatment of BAC.
Researchers at Cedars-Sinai Medical Center developed a molecular test that identified a panel of genes correlating with tumor response to gefitinib, a drug approved for shrinking tumors in advanced lung cancer. The study found distinct patterns of gene expression linked to patient responses or lack thereof.
Researchers found that gefitinib can slow lung cancer tumor recurrence when used as maintenance therapy following chemotherapy. The study suggests that gefitinib may keep cancer cells dormant for a period of time.
A combination of bevacizumab and erlotinib has shown a 21 percent response rate in patients with recurrent stage IIIb or IV lung cancer, with five patients experiencing partial responses and tumor stabilization for over a year. The treatment was well-tolerated with mild to moderate toxicity.
A new radiotherapy strategy, hyperfractionated accelerated radiotherapy (HART), has been shown to improve survival rates for lung cancer patients. In a phase III multi-site study, chemotherapy followed by HART resulted in a median survival of 21 months, compared to 12 months with standard radiation therapy.
In a Phase II clinical trial, C225 and docetaxel combination achieved a 25.5% tumor shrinkage rate in advanced non-small cell lung cancer patients, significantly higher than the median response rate of 5-10%. The results are encouraging and suggest further development of this treatment approach.
A study by Chandra P. Belani and colleagues found that elderly patients with advanced NSCLC can tolerate combination therapy safely and effectively, with median survival rates comparable to those of younger patients. The treatment regimens used in the study were weekly paclitaxel in combination with full doses of carboplatin.
A new randomized study found that beta-carotene supplementation increased cancer risk in smokers and drinkers, while decreasing risk in non-smokers and non-drinkers. The study's findings highlight the complexity of designing safe and effective chemopreventive strategies for any cancer.
Researchers treated 18 patients with lung nodules using radiofrequency ablation, achieving a 97% destruction rate. The treatment was found to be short-lasting and manageable, with most complications resolved within a week.
The Stanford study found that FDG-PET is highly effective for lung nodule diagnosis but most cost-effective when used selectively with CT scans. The researchers recommend relying on CT as the initial test for almost all patients and using FDG-PET in cases where the risk of cancer conflicts with CT results.